Chronic Kidney Disease Trial, Recruiting NCT06383208 Sponsor: China-Japan Friendship Hospital Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT06383208
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years old
  • People who have been diagnosed with coronary heart disease during a hospital stay through a procedure that looks at the heart's arteries (coronary angiography), including heart attacks with a specific pattern on a heart tracing (STEMI), other types of acute heart conditions without that pattern (NST-ACS), or stable chest pain (stable angina)
  • People whose kidney function has been clearly assessed, including those with chronic kidney disease defined as having reduced kidney filtering ability or elevated levels of a protein called albumin in the urine, lasting more than 3 months (confirm with trial site for exact measurements)

Who may not be able to join:

  • People who are pregnant or breastfeeding
  • People with severe heart valve disease or serious heart complications that require surgery
  • People with severe mental illness or other reasons that would make it difficult to attend follow-up appointments
  • People with serious blood disorders or advanced-stage cancer
  • People who have had a kidney transplant or who are on long-term dialysis
  • People with severe liver disease (a specific medical classification called Child-Pugh class C)
  • People who received dialysis treatment for sudden kidney failure within the 12 weeks before joining the trial
  • People with severe chronic lung disease requiring long-term breathing machine support or who are waiting for a lung transplant
  • People whose life expectancy is less than one year

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Zheng Jingang, MD, China-Japan Friendship Hospital

Phone: +86 13882712184

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
China-Japan Friendship Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2024
Est. completion
31 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of cardiovascular adverse events; Incidence of Renal composite endpoint event

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov